Advanced search
Publication Cover
International Reviews of Immunology Volume 21, 2002 - Issue 2-3
Submit an article Journal homepage
47
Views
44
CrossRef citations to date
0
Altmetric
Research Article

BENCH TO BEDSIDE: NEW APPROACHES TO THE IMMUNOTHERAPY OF UVEITIC DISEASE

ROBERT B. NUSSENBLATT Laboratory of Immunology, National Institute of Health, Bethesda, Maryland, USA
Pages 273-289 | Published online: 03 Aug 2009

  • R. Nussenblatt, K. Mittal, S. Ryan, W. Green, and A. Maumenee, Birdshot retinochoroidopathy-An association with HAL-A29 and immune responsiveness to retinal S-antigen. Am. J. Ophthalmol., 94: 147-158, 1982.
  • D. Jabs, J. Rosenbaum, C. Foster, G. Holland, G. Jafee, J. Louie, R. Nussenblatt, E. Stiehm, H. Tessler, R. VanGelder, S. Whitcup, and D. Yocum, Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders. Am. J. Ophthalmol., 130: 492-513, 2000.
  • P. Brandtzaeg, Development and basic mechanisms of human gut immunity. Nutr. Rev., 56: S5-S18, 1998.
  • G. Macfarlaneand S. Macfarlane, Human colonic microbiota: Ecology, physiology and metabolic potential of intestinal bacteria. Scand. J. Gastroenterol. Suppl., 222: 3-9, 1997.
  • C. Nagler-Anderson, L. Bober, M. Robinson, G. Siskind, and F. Thorbeke, Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc. Natl. Acad. Sci. USA, 83: 7443-7446, 1986.
  • A. Besredka, De l'anaphylaxie. Sixième memoire de l'anaphylaxie lactique. Ann. Inst. Pasteur, 23: 166-174, 1909.
  • M. Chase, Inhibition of experimental drug allergy by prior feeding of the sensitizing agent. Proc. Soc. Exp. Biol. Med., 61: 257-259, 1946.
  • D. Bitarand C. Whitacre, Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell. Immunol., 112: 364-370, 1988.
  • P. Higginsand H. Weiner, Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J. Immunol., 140: 440-445, 1988.
  • H. Weiner, Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol. Today, 18: 335-343, 1997.
  • R. Daynes, B. Araneo, T. Dowell, K. Huang, and D. Dudley, Regulation of murien lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. J. Exp. Med., 171(4): 979-996, 1990.
  • J. Benson, K. Campbell, Z. Guan, I. Gienapp, S. Stuckman, T. Forsthuber, and C. Whitacre, T-cell activation and receptor downmodulation precede deletion induced by mucosally administered antigen. J. Clin. Invest., 106(8): 1031-1038, 2000.
  • R. Nussenblatt, R. Caspi, R. Mahdi, C.-C. Chan, F. Roberge, O. Lider, and H. Weiner, Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J. Immunol., 144(5): 1689-1695, 1990.
  • P. Silver, L.S. Rizzo, C.-C. Chan, B. Wiggert, R. Nussenblatt, and R. Caspi, Heterologous epitopes of IRBP protect against autoimmune uveitis induced by the autologous epitope. J. Neuroimmunol., 88: 128-136, 1998.
  • S. Thurau, C.-C. Chan, R. Nussenblatt, and R. Caspi, Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): Induction of protective tolerance in primed animals. Clin. Exp. Immunol., 109(2): 370-376, 1997.
  • L. Rizzo, R. Morawetz, N. Miller-Rivero, R. Choi, B. Wiggert, C.-C. Chan, H. Morse, R. Nussenblatt, and R. Caspi, IL-4 and IL-10 are both required for the induction of oral tolerance. J. Immunol., 162: 2613-2622, 1999.
  • L. Rizzo, N. Miller-Rivero, C.-C. Chan, B. Wiggert, R. Nussenblatt, and R. Caspi, Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J. Clin. Invest., 94(4): 1668-1672, 1994.
  • R. Nussenblatt, I. Gery, H. Weiner, F. Ferris, J. Shiloach, N. Remaley, C. Perry, R. Caspi, D. Hafler, C. Foster, and S. Whitcup, Treatment of uveitis by oral administration of retinal antigens: Results of a phase I/II randomized masked trial. Am. J. Ophthalmol., 123(5): 583-592, 1997.
  • J. Benson, S. Stuckman, K. Cox, R. Wardrop, I. Gienapp, A. Cross, J. Trotter, and C. Whitacre, Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis. J. Immunol, 162(10): 6247-6254, 1999.
  • H. Weiner, H.G. Mackin, M. Matsui, E. Orav, S. Khoury, D. Dawson, and D. Hafler, Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science, 259: 1321-1324, 1993.
  • R. Caspi, F. Roberge, C. McAllister, M. El-Saied, T. Kuwabara, I. Gery, E. Hanna, and R. Nussenblatt, T-cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J. Immunol., 136: 928-933, 1986.
  • R.B. Nussenblatt, M.M. Rodrigues, W.B. Wacker, S.J. Cevario, M.C. SalinasCarmona, and I. Gery, Cyclosporin A: Inhibition of experimental autoimmune uveitis in Lewis rats. J. Clin. Invest., 67: 1228-1231, 1981.
  • R.B. Nussenblatt, A.G. Palestine, A.H. Rook, and I. Scher, Cyclosporine therapy for intra-ocular inflammatory disease. Lancet, ii: 235-238, 1983.
  • C. Queen, W. Schneider, H. Selick, et al., A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA, 86: 10029-10033, 1989.
  • M. Reed, M. Shapiro, T. Strom, et al., Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. Transplantation, 47: 55-59, 1989.
  • P.J. Brown, G. Parenteau, F. Dirbas, et al., Anti-Tac-H, a humanized antibody to the Interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc. Natl. Acad. Sci. USA, 88: 2663-2667, 1991.
  • P. Herve, J. Wijdenes, J. Bergerat, et al., Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood, 75: 1017-1023, 1990.
  • F. Vincenti, R. Kirkman, S. Light, G. Bumgardner, M. Pescovitz, H. P, J. Neylan, A. Wilkinson, H. Ekberg, R. Gaston, L. Backman, J. Burdick, and for the Daclizumab Triple Therapy Study Group., Interleukin-2-receptor blockade with Daclizumab to prevent acute rejection in renal transplantation. N. Engl. J. Med., 338: 161-165, 1998.
  • Y. Guex-Crosier, J. Raber, C.-C. Chan, M. Knete, J. Benichou, R. Pilsen, J. Kerwin, T. Waldmann, J. Hakimi, and F. Roberge, Humanized antibodies against the alphachain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J. Immunol., 158(1): 452-458, 1997.
  • H. BehU00E7et, Über Rezide, Viereude, Aphthose, durchein Virus verursache Geshwure am Mund, am Auge, und audeu Genitalien. Dermatol. Wochenschr., 46: 414-419, 1937.
  • Behçet's Disease Research Committee, Clinical research section recommendations. Jpn. J. Ophthalmol., 18: 291-294, 1974.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.